Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04926779 · ClinicalTrials.gov registry record · NA
Study Utilizing BIOZEK COVID-19 Antigen Rapid Test
A NA study of COVID-19 Testing, sponsored by Mach-E B.V..
- Completed
- Registry status
- NA
- Development phase
- 185
- Enrollment target
- 2
- Study locations
NCT04926779: Completed NA study of COVID-19 Testing, sponsored by Mach-E B.V..
NCT04926779 is a NA study of COVID-19 Testing that has completed, run by Mach-E B.V.. The registered enrollment target is 185 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (87% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04926779, a NA study of COVID-19 Testing, has completed, sponsored by Mach-E B.V..
- COMPLETED
- Registry status
- NA
- Development phase
- 185 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a research study to evaluate the Sensitivity and Specificity of BIOZEK COVID-19 Antigen Rapid Test (Saliva) and BIOZEK COVID-19 Antigen Rapid Test (Nasopharyngeal Swab) on samples that are self-collected; and to perform analysis to compare results. In addition, to obtain RT-PCR test results, performed prior to enrollment, and compare all three results.
Primary Outcome
The Biozek Antigen Rapid Tests performed by subjects on the self-collected, oral fluid samples . Sensitivity was calculated using (TP/TP+FN)\*100% formula. Specificity was calculated using (TN/TN+FP)\*100% formula.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Biozek Covid-19 Antigen Rapid Test (Saliva)
Study Locations (2)
New York
- Mobile Covid Services LLC - Flushing
- Quality Research and Invention LLC - Southampton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 185 participants |
| Start Date | 2021-05-24 |
| Est. Completion | 2022-11-04 |
| Phase | NA |
What the finished NCT04926779 record still lists
NCT04926779 is an interventional study that assigns participants to a tested intervention. The registered 185 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (87% lower).
The record links to 1 condition, with COVID-19 Testing appearing as the primary indexed condition, and to 1 intervention - of which Biozek Covid-19 Antigen Rapid Test (Saliva) is the first listed.
NCT04926779 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT04926779 about?
NCT04926779 is a clinical study titled "Study Utilizing BIOZEK COVID-19 Antigen Rapid Test". This is a research study to evaluate the Sensitivity and Specificity of BIOZEK COVID-19 Antigen Rapid Test (Saliva) and BIOZEK COVID-19 Antigen Rapid Test (Nasopharyngeal Swab) on samples that are self-collected; and to perform analysis to compare results. In addition, to obtain RT-PCR test results,...
What is the current status of trial NCT04926779?
This trial is currently completed. It is a NA study. The enrollment target is 185 participants. The study started on 2021-05-24. Estimated completion is 2022-11-04.
What conditions does trial NCT04926779 study?
This clinical trial studies the following conditions: COVID-19 Testing.
What interventions are being tested in trial NCT04926779?
The interventions under investigation include: Biozek Covid-19 Antigen Rapid Test (Saliva) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04926779?
This trial is sponsored by Mach-E B.V., which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04926779 being conducted?
This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19 Testing
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04926779's enrollment target sits among peer trials
185 580th of 2000 higher than 1,420 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04041154 · 185 participants · NA
Behavioral and Neural Representations of Subjective Effort Cost
- NCT04484272 · 185 participants · NA
A Stress and Pain Self-management m-Health App for Adult Outpatients With Sickle Cell Disease
- NCT05020860 · 185 participants · Phase 2
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
- NCT05793541 · 185 participants · NA
Just-in-time Interventions for Reducing Short-term Suicide Risk
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI